Comparison of the efficacy of osimertinib and ametinib

Osimertinib and Aumolertinib are both third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), mainly used to treat patients with non-small cell lung cancer carrying EGFR mutations. Both have shown good efficacy in inhibiting EGFR sensitive mutations and drug-resistant mutations T790M, and are currently important clinically targeted drugs for EGFR mutation-positive lung cancer.

In terms of efficacy performance, osimertinib, as the first approved third-generation EGFR-TKI, has become the standard drug for lung cancer treatment worldwide due to its significant prolongation of progression-free survival (PFS) and overall survival (OS). Osimertinib not only can effectively penetrate the blood-brain barrier, but also has a good therapeutic effect on patients with brain metastases. It can also reduce the inhibition of wild-type EGFR, reduce the incidence of side effects, and improve the quality of life of patients.

Ametinib is a domestically produced third-generation EGFR-TKI. Clinical trial data shows that its efficacy is similar to that of osimertinib in the treatment of patients with EGFR mutation-positive non-small cell lung cancer. Ametinib also has good blood-brain barrier penetration ability, can effectively control brain metastases, and shows good tolerability in terms of safety. Due to its relatively more advantageous price, ametinib provides an economical and effective treatment option for some patients.

Taken together, osimertinib and ametinib both performed outstandingly in terms of efficacy, especially in prolonging progression-free survival and controlling brain metastasis. Osimertinib still occupies a leading position with its globally recognized clinical data and wide application, while ametinib has become an important alternative for domestic patients with its good efficacy, safety and economy. Patients should choose the most suitable treatment drug based on their own situation, financial conditions and doctor's advice.

Reference materials:https://go.drugbank.com/drugs/DB09330